Table 4.
Major side effects observed during the intravenous and oral phases of CsA administration
| Adverse event | Outcome | N (%) | Treatment Phase |
| Pulmonary Embolism | Death | 1 (2.5%) | Intravenous |
| >33% ↑ creatinine | Dose maintained | 7 (17%) | Oral |
| 2 × creatinine | Dose reduced | 1 (2.5%) | Oral |
| Biliary sludge | Drug discontinued | 2 (5%) | Intravenous |
| ↑ liver function tests | Dose maintained | 2 (5%) | Intravenous |
| Seizures | Dose maintained | 1 (2.5%) | Oral |